Developing a regenerative therapy that can expand pancreatic β-cell mass, boost endogenous insulin production, and restore glucose homeostasis presents a transformative opportunity for diabetes treatment, where β-cell loss is a contributing factor to disease progression (1, 2, 3). The gene discussed is INS; the disease is diabetes mellitus.